



5 February 2007

**PuriCore Signs Exclusive UK Distribution Agreement with Minntech Corporation
to Expand its Sterilox Endoscopy Portfolio**

PuriCore (LSE: PURI), the life sciences company focused on the development and commercialisation of its novel, safe antimicrobial technology, today announces that its Sterilox Endoscopy division has signed an exclusive distribution agreement with Minntech Corporation ("Minntech"), one of the world's leading manufacturers of automated endoscope reprocessors ("AER"), and a subsidiary of Cantel Medical Corp (NYSE: CMN).

This partnership significantly enhances PuriCore's product portfolio combining its award winning Sterilox Solution with Minntech's MDS reprocessor systems, the latest innovation in asynchronous AER technology.

Under the terms of the agreement, PuriCore is responsible for distributing and servicing Minntech's endoscopy reprocessing portfolio, including its new MDS AER, to UK hospitals. Minntech's UK sales and technical support team will become employees of PuriCore's Sterilox Endoscopy division, and Sterilox Endoscopy will now service Minntech's installed base of approximately 125 AERs in UK hospitals, bringing PuriCore's total AER network to circa 600, representing an estimated 33% of the installed AER market. Additionally, Sterilox Endoscopy now has the opportunity to expand its market penetration strategy into the asynchronous AER segment, which represents around 27% of the total UK AER market. The agreement is effective immediately.

Greg Bosch, Chief Executive of PuriCore, said:

"Our partnership with Minntech reflects the next step in the evolution of our Sterilox Endoscopy business. Together, the combined strength of our products, teams, and installed base will enable us to respond better to market demands in the UK. This combination further strengthens Sterilox Endoscopy's position as the UK's leading provider of endoscopy reprocessing systems."

Roy K. Malkin, President and CEO of Minntech Corporation, said:

"We are very pleased with the past performance of our Minntech UK team, and are extremely excited about our new partnership with Sterilox Endoscopy that will allow us to even better serve our long term customers in the UK. I am confident that Sterilox Endoscopy is well positioned to market and service our products in the UK, and in the not too distant future, we look forward to launching a dedicated Minntech MDS reprocessor for use with the Sterilox Solution that promises to provide the absolute best alternative for our mutual endoscopy customers."

"We will be working closely with the Sterilox Endoscopy team to ensure a seamless transition of customer support."

Contacts:**PuriCore plc**

Greg Bosch, Chief Executive Officer
Keith A. Goldan, Chief Financial Officer

+1 (484) 321-2700**Financial Dynamics**

Ben Brewerton
John Gilbert

Tel: +44 (0) 20 7831 3113

Notes to Editors: Sterilox Endoscopy is a division of PuriCore.

About PuriCore

PuriCore (LSE: PURI) is a life sciences company focused on the development and commercialisation of its proprietary technology that mimics the production by the human body of its natural anti-microbial, hypochlorous acid. Hypochlorous acid is highly effective at killing pathogens such as bacteria, viruses and fungi and yet is safe and environmentally friendly. PuriCore's solutions have applications in a wide range of markets where it is important to control microbial contamination. These markets include medical device disinfection, food safety, dental equipment decontamination, environmental remediation, hospitality, water safety, wound management and other applications intended to limit the spread of infectious disease, including major global disease threats such as Tuberculosis, MRSA, Influenza, E.coli, Norovirus, HIV, polio, Hepatitis A, H.pylori and Legionella.

PuriCore markets a portfolio of branded systems which produce hypochlorous acid solutions on-site at a customer's location from water, electricity and common salt. These solutions are generated at a range of concentrations and at a nearly neutral pH range similar to the human body. They are effective as soaks, sprays, mists and in other forms.

PuriCore is headquartered in Malvern, Pennsylvania with offices in Stafford, UK.

To receive additional information on PuriCore or its Sterilox Endoscopy division, please visit our web site at www.puricore.com, which does not form part of this press release.

About Minntech

Minntech is one of the world's leading manufacturers of endoscopy AERs with over 62% of the US GI market and a strong European distribution network. The company was founded in 1974, and since 2001 has been a part of Cantel Medical Corp., a leading provider of infection prevention and control products in the healthcare market. Cantel's products include specialized medical device reprocessing systems for renal dialysis and endoscopy, dialysate concentrates and other dialysis supplies, disposable infection control products primarily for the dental industry, water purification equipment, sterilants, disinfectants and cleaners, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. Cantel also provides technical maintenance for its products and offers compliance training services for the transport of infectious and biological specimens.